Key result
Higher blood cadmium is linked to ~21% greater risk of CKM syndrome progression.
Why the study?
Does higher cadmium exposure increase the risk of CKM syndrome progression and all-cause mortality in adults?
Observational (n=5,865)
Yes
Does higher cadmium exposure increase the risk of CKM syndrome progression and all-cause mortality in adults?
Odds Ratio: 1.21 (95% CI 1.05–1.4)
Cadmium exposure is a significant risk factor for the progression of Cardiovascular-Kidney-Metabolic syndrome and increases all-cause mortality in advanced stages.
While metal exposures are linked to cardiovascular and renal diseases, their role in cardiorenal comorbidity remains poorly understood. Using the American Heart Association's Cardiovascular-Kidney-Metabolic Syndrome (CKM syndrome) framework, we combined population epidemiology and Adverse Outcome Pathway (AOP) analysis to explore how cadmium exposure influences CKM progression and advanced-stage outcomes. Data from 5865 adults aged 30-79 years in the National Health and Nutrition Examination Surveys (NHANES) were analyzed to investigate serum metal exposure patterns and CKM syndrome progression. Logistic regression showed that higher blood cadmium levels were associated with CKM progression (OR = 1.21, 95 % CI = 1.05-1.40), highlighting cadmium as a key risk factor. Subsequent Cox proportional hazards regression analyses demonstrated amplified effects of cadmium exposure on all-cause mortality in advanced-stage CKM patients (HR = 1.30, 95 % CI = 1.09-1.56). To mechanistically characterize Cd-induced CKM syndrome progression and advanced-stage outcomes, we constructed a Chemical-Gene-Phenotype-Disease (CGPD) network through integrative mining of the Comparative Toxicogenomics Database (CTD) and GeneCards databases. This was synergistically combined with AOP-Wiki and PubMed databases to establish an AOP framework. This investigation represents the first study combining population epidemiology with AOP methodology to delineate the multi-organ interaction mechanisms between metal exposure (Cd) and CKM syndrome. This study not only furnishes a novel evidence base for risk assessment of metal exposure, but also establishes a paradigmatic reference for constructing adverse outcome pathway (AOP) frameworks across multiple organ systems, demonstrating significant public health implications.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted an observational in Cardiovascular-Kidney-Metabolic Syndrome (CKM syndrome) (n=5,865). Cadmium exposure vs. Lower cadmium exposure was evaluated on CKM progression (OR 1.21, 95% CI 1.05-1.40). Higher blood cadmium levels were associated with Cardiovascular-Kidney-Metabolic syndrome progression (OR 1.21; 95% CI 1.05-1.40) and increased all-cause mortality in advanced-stage patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: